Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults
Purpose Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15–39 years old). However, HRD score, indicating HRD status, is not routinely asses...
Saved in:
| Published in | Breast cancer research and treatment Vol. 182; no. 2; pp. 491 - 502 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.07.2020
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Purpose
Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15–39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline
BRCA1/2
mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors.
Methods
Subjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score ≥ 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting.
Results
In all three cohorts, the HRD-high phenotype was associated with germline
BRCA1/2
mutation, somatic
TP53
mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline
BRCA1/2
mutation also yielded high-predictive power in cases from these two cohorts without germline
BRCA1/2
mutations: AUC was 0.92 and 0.90, respectively.
Conclusions
The HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline
BRCA1/2
mutations. |
|---|---|
| AbstractList | Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15-39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors.PURPOSEHomologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15-39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors.Subjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score ≥ 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting.METHODSSubjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score ≥ 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting.In all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively.RESULTSIn all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively.The HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations.CONCLUSIONSThe HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations. Purpose Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15-39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors. Methods Subjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score [greater than or equal to] 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting. Results In all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively. Conclusions The HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations. Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15-39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors. Subjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score [greater than or equal to] 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting. In all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively. The HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations. Purpose Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15–39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors. Methods Subjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score ≥ 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting. Results In all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively. Conclusions The HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations. PurposeHomologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15–39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors.MethodsSubjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score ≥ 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting.ResultsIn all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively.ConclusionsThe HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations. Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15-39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors. Subjects were our own cohort of 46 Japanese AYA breast cancer patients and two existing breast cancer cohorts of US and European patients. Models for prediction of the HRD-high phenotype, defined as HRD score ≥ 42, were constructed by logistic regression analysis, using as explanatory variables genetic and clinicopathological factors assessable in the clinical setting. In all three cohorts, the HRD-high phenotype was associated with germline BRCA1/2 mutation, somatic TP53 mutation, triple-negative subtype, and higher tumor grade. A model based on these four factors, developed using the US cohort, was validated in the Japanese and European AYA cases: area under the receiver operating characteristic curve [AUC] was 0.90 and 0.96, respectively. A model based on three factors excluding germline BRCA1/2 mutation also yielded high-predictive power in cases from these two cohorts without germline BRCA1/2 mutations: AUC was 0.92 and 0.90, respectively. The HRD-high phenotype of AYA breast cancer patients can be deduced from genomic and pathological factors that are routinely examined in the oncology clinic, irrespective of germline BRCA1/2 mutations. |
| Audience | Academic |
| Author | Arai, Eri Kohno, Takashi Shimada, Yoko Ushiama, Mineko Totsuka, Hirohiko Kanai, Yae Shiraishi, Kouya Watanabe, Tomoko Tanioka, Maki Yoshida, Masayuki Honda, Takayuki Yoshida, Teruhiko Tamura, Kenji |
| Author_xml | – sequence: 1 givenname: Tomoko surname: Watanabe fullname: Watanabe, Tomoko organization: Division of Genome Biology, National Cancer Center Research Institute, Department of NCC Cancer Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Department of Genetic Medicine and Services, National Cancer Center Hospital – sequence: 2 givenname: Takayuki surname: Honda fullname: Honda, Takayuki organization: Division of Genome Biology, National Cancer Center Research Institute, Department of Respiratory Medicine, Tokyo Medical and Dental University – sequence: 3 givenname: Hirohiko surname: Totsuka fullname: Totsuka, Hirohiko organization: StaGen Co., Ltd – sequence: 4 givenname: Masayuki surname: Yoshida fullname: Yoshida, Masayuki organization: Pathology Division, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital – sequence: 5 givenname: Maki surname: Tanioka fullname: Tanioka, Maki organization: Department of Breast and Medical Oncology, National Cancer Center Hospital – sequence: 6 givenname: Kouya surname: Shiraishi fullname: Shiraishi, Kouya organization: Division of Genome Biology, National Cancer Center Research Institute – sequence: 7 givenname: Yoko surname: Shimada fullname: Shimada, Yoko organization: Division of Genome Biology, National Cancer Center Research Institute – sequence: 8 givenname: Eri surname: Arai fullname: Arai, Eri organization: Department of Pathology, Keio University School of Medicine – sequence: 9 givenname: Mineko surname: Ushiama fullname: Ushiama, Mineko organization: Department of Genetic Medicine and Services, National Cancer Center Hospital, Department of Clinical Genomics, Fundamental Innovative Oncology Core, National Cancer Center Research Institute – sequence: 10 givenname: Kenji surname: Tamura fullname: Tamura, Kenji organization: Department of Breast and Medical Oncology, National Cancer Center Hospital – sequence: 11 givenname: Teruhiko surname: Yoshida fullname: Yoshida, Teruhiko organization: Department of Genetic Medicine and Services, National Cancer Center Hospital – sequence: 12 givenname: Yae surname: Kanai fullname: Kanai, Yae organization: Department of Pathology, Keio University School of Medicine – sequence: 13 givenname: Takashi orcidid: 0000-0002-5371-706X surname: Kohno fullname: Kohno, Takashi email: tkkohno@ncc.go.jp organization: Division of Genome Biology, National Cancer Center Research Institute, Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32488393$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk9r3DAQxUVJaTZpv0APxVAovTgdSZYlH0PoPwj00PYsZHm8qyBLG8k-7LePdjdtk1CCDoLh90ZPM--MnIQYkJC3FC4ogPyUKYimq4FBDULStoYXZEWF5LVkVJ6QFdBW1q2C9pSc5XwDAJ2E7hU55axRind8RW5_umnrsdomHJydXQzVFAf01RhTtYlT9HEdl1wltHHqXTAHZMDRWYfB7ioXqj6hyXNlTbCY8r5ihugxWwxzrkwYql1cwrpUFz_n1-TlaHzGN_f3Ofn95fOvq2_19Y-v368ur2sreDfXwrSMMqBN19sWDVpmBGNoRWsVKCEGOppRNqqjoqEMeW-kMILCyHsleznwc_Lx2Heb4u2CedaTK5a8NwHLjzRroKMd7zpZ0PdP0Ju4pFDcFYpyBdCIB9TaeNQujHFOxu6b6suWtUpyoaBQF_-hyhlwcrYscHSl_kjw4YFgg8bPmxz9sh90fgy-u3e59BMOepvcZNJO_1lmAdgRsCnmnHD8i1DQ-8ToY2J0SYw-JEbvu6onIuvmw5aLb-efl_KjNJd3whrTv7E9o7oDqRnS8Q |
| CitedBy_id | crossref_primary_10_1007_s10549_023_07102_y crossref_primary_10_1186_s40364_024_00653_2 crossref_primary_10_1016_j_tranon_2020_100986 |
| Cites_doi | 10.1056/NEJMoa1802905 10.4143/crt.2018.132 10.1056/NEJMoa1910962 10.1038/s41586-019-1382-1 10.1111/cas.13486 10.1056/NEJMoa1706450 10.1056/NEJMoa1909707 10.1056/NEJMoa1813904 10.1111/j.1365-2559.1991.tb00229.x 10.1016/j.cell.2018.02.052 10.1200/jco.2014.57.0085 10.1056/NEJMoa1911361 10.1002/jso.25457 10.1016/j.cell.2018.03.039 10.1126/scitranslmed.aaa7161 10.1073/pnas.1009843107 10.1158/1535-7163.Mct-15-0230 10.1158/1078-0432.Ccr-15-2477 10.1186/s13059-019-1867-0 10.1186/s40364-015-0033-4 10.1007/s12282-013-0466-2 10.1186/s13059-016-0893-4 10.1126/science.aam7344 10.1186/s13053-019-0111-y 10.1158/1078-0432.Ccr-13-2287 10.1016/s0140-6736(17)32440-6 10.1038/nm.4333 10.1111/cas.13969 10.1038/nrm1546 10.1200/jco.2007.14.4147 10.1158/0008-5472.Can-12-2753 10.1038/s41523-018-0066-6 10.1126/scitranslmed.3003161 10.1056/NEJMoa1611310 10.1200/JCO.2018.36.15_suppl.519 10.1038/ng.2762 10.1038/s41467-018-04129-4 10.1038/s41591-018-0009-7 10.1016/s1470-2045(11)70214-5 10.1007/s10549-018-05120-9 10.1002/humu.23035 10.1200/jco.2006.10.3754 10.1038/nm.4292 10.1038/nature11412 10.1200/jco.2014.57.6660 10.18632/oncotarget.23765 10.1200/jco.2015.65.0747 10.1016/j.celrep.2018.03.076 10.1038/ng.3934 10.1200/jco.2015.65.8013 10.1056/NEJMoa0900212 10.1038/nature17676 10.1016/s1470-2045(16)30559-9 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2020 COPYRIGHT 2020 Springer Springer Science+Business Media, LLC, part of Springer Nature 2020. |
| Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2020 – notice: COPYRIGHT 2020 Springer – notice: Springer Science+Business Media, LLC, part of Springer Nature 2020. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9- K9. M0R M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1007/s10549-020-05716-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts Consumer Health Database (Alumni) ProQuest Health & Medical Complete (Alumni) Consumer Health Database ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1573-7217 |
| EndPage | 502 |
| ExternalDocumentID | A626873580 32488393 10_1007_s10549_020_05716_0 |
| Genre | Validation Study Multicenter Study Journal Article |
| GeographicLocations | United States Europe Japan United States--US |
| GeographicLocations_xml | – name: Europe – name: Japan – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development grantid: JP19ck0106402; 19cm0106605 funderid: http://dx.doi.org/10.13039/100009619 – fundername: The National Cancer Center Research and Development Fund grantid: 30-A-6 – fundername: The Ishidsu Shun Memorial Scholarship grantid: No data – fundername: The Sasakawa Scientific Research Grant (Japan Science Society) grantid: 2019-6014 – fundername: Japan Agency for Medical Research and Development grantid: JP19ck0106402 – fundername: Japan Agency for Medical Research and Development grantid: 19cm0106605 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -XW -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKNYI BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICW IHE IHR IHW IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAK LLZTM M0R M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z7W Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM AEIIB PMFND 7TO 7XB 8FK ABRTQ H94 K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c539t-5a62120149bc6eaec2a522ec56c80855d1faf748915412e3ba75a510f3b87b7d3 |
| IEDL.DBID | U2A |
| ISSN | 0167-6806 1573-7217 |
| IngestDate | Fri Jul 11 12:08:10 EDT 2025 Sat Aug 23 12:28:46 EDT 2025 Tue Jun 17 20:59:36 EDT 2025 Tue Jun 10 20:50:48 EDT 2025 Thu May 22 21:17:50 EDT 2025 Thu Apr 03 07:04:36 EDT 2025 Thu Apr 24 23:01:38 EDT 2025 Tue Jul 01 03:38:03 EDT 2025 Fri Feb 21 02:31:48 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Insurance reimbursement Breast cancer Adolescent and young adult (AYA) Homologous recombination deficiency |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-5a62120149bc6eaec2a522ec56c80855d1faf748915412e3ba75a510f3b87b7d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-5371-706X |
| PMID | 32488393 |
| PQID | 2413800457 |
| PQPubID | 36266 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2409193997 proquest_journals_2413800457 gale_infotracmisc_A626873580 gale_infotracacademiconefile_A626873580 gale_healthsolutions_A626873580 pubmed_primary_32488393 crossref_primary_10_1007_s10549_020_05716_0 crossref_citationtrail_10_1007_s10549_020_05716_0 springer_journals_10_1007_s10549_020_05716_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-01 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: Netherlands – name: Dordrecht |
| PublicationTitle | Breast cancer research and treatment |
| PublicationTitleAbbrev | Breast Cancer Res Treat |
| PublicationTitleAlternate | Breast Cancer Res Treat |
| PublicationYear | 2020 |
| Publisher | Springer US Springer Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
| References | CarameloOSilvaCCarameloFFrutuosoCAlmeida-SantosTThe effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysisHered Cancer Clin Pract2019171110.1186/s13053-019-0111-y3096285830962858 KanZDingYKimJJungHHChungWLalSChoSFernandez-BanetJLeeSKKimSWLeeJEChoiYLDengSKimJYAhnJSShaYMuXJNamJYImYHLeeSParkWYNamSJParkYHMulti-omics profiling of younger Asian breast cancers reveals distinctive molecular signaturesNat Commun20189117251:CAS:528:DC%2BC1cXhtFeltL%2FL10.1038/s41467-018-04129-42971300329713003 TuttAToveyHCheangMCUKernaghanSKilburnLGazinskaPOwenJAbrahamJBarrettSBarrett-LeePBrownRChanSDowsettMFlanaganJMFoxLGrigoriadisAGutinAHarper-WynneCHattonMQHoadleyKAParikhJParkerPPerouCMRoylanceRShahVShawASmithIETimmsKMWardleyAMWilsonGGillettCLanchburyJSAshworthARahmanNHarriesMEllisPPinderSEBlissJMCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialNat Med20182456286371:CAS:528:DC%2BC1cXovVWrsrs%3D10.1038/s41591-018-0009-72971308629713086 DaviesBRGuanNLogieACrafterCHansonLJacobsVJamesNDudleyPJacquesKLaddBD'CruzCMZindaMLindemannJKodairaMTamuraKJenkinsELTumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitorsMol Cancer Ther20151411244124511:CAS:528:DC%2BC2MXhslOgt7%2FO10.1158/1535-7163.Mct-15-02302635132326351323 Nik-ZainalSDaviesHStaafJRamakrishnaMGlodzikDZouXMartincorenaIAlexandrovLBMartinSWedgeDCVan LooPJuYSSmidMBrinkmanABMorganellaSAureMRLingjaerdeOCLangerodARingnerMAhnSMBoyaultSBrockJEBroeksAButlerADesmedtCDirixLDronovSFatimaAFoekensJAGerstungMHooijerGKJangSJJonesDRKimHYKingTAKrishnamurthySLeeHJLeeJYLiYMcLarenSMenziesAMustonenVO'MearaSPauporteIPivotXPurdieCARaineKRamakrishnanKRodriguez-GonzalezFGRomieuGSieuwertsAMSimpsonPTShepherdRStebbingsLStefanssonOATeagueJTommasiSTreilleuxIVan den EyndenGGVermeulenPVincent-SalomonAYatesLCaldasCVant VeerLTuttAKnappskogSTanBKJonkersJBorgAUenoNTSotiriouCViariAFutrealPACampbellPJSpanPNVan LaereSLakhaniSREyfjordJEThompsonAMBirneyEStunnenbergHGvan de VijverMJMartensJWBorresen-DaleALRichardsonALKongGThomasGStrattonMRLandscape of somatic mutations in 560 breast cancer whole-genome sequencesNature2016534760547541:CAS:528:DC%2BC28XntVCksrc%3D10.1038/nature176762713592627135926 RosenthalRMcGranahanNHerreroJTaylorBSSwantonCDeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolutionGenome Biol201617311:CAS:528:DC%2BC28XpvVCltL0%3D10.1186/s13059-016-0893-42689917026899170 LittonJKRugoHSEttlJHurvitzSAGoncalvesALeeKHFehrenbacherLYerushalmiRMinaLAMartinMRocheHImYHQuekRGWMarkovaDTudorICHannahALEiermannWBlumJLTalazoparib in patients with advanced breast cancer and a germline BRCA mutationNew Engl J Med201837987537631:CAS:528:DC%2BC1cXhs1eqsrnI10.1056/NEJMoa18029053011057930110579 Cancer Information Service, National Cancer Center, Japan (2019) Cancer registry and statistics. https://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed 17 May 2019. U.S. Food and Drug Administration (2017) FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.html. Accessed 10 May 2019 IsakoffSJMayerELHeLTrainaTACareyLAKragKJRugoHSLiuMCStearnsVComeSETimmsKMHartmanARBorgerDRFinkelsteinDMGarberJERyanPDWinerEPGossPEEllisenLWTBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancerJ Clin Oncol20153317190219091:CAS:528:DC%2BC2MXhsFKmt7zM10.1200/jco.2014.57.66602584793625847936 AndreFCiruelosERubovszkyGCamponeMLoiblSRugoHSIwataHContePMayerIAKaufmanBYamashitaTLuYSInoueKTakahashiMPapaiZLonginASMillsDWilkeCHirawatSJuricDAlpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancerN Engl J Med201938020192919401:CAS:528:DC%2BC1MXhtVWis7nP10.1056/NEJMoa1813904 TelliMLMetzgerOTimmsKEvansBVogelDWeiHJonesJTWenstrupRJMcKeeMDSullivanDMFallstromMMaagDAnsellPJSohnJChenS-TMartinezNGeyerCELoiblSGolshanMEvaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBCJ Clin Oncol20183615_suppl51951910.1200/JCO.2018.36.15_suppl.519 AhnSHSonBHKimSWKimSIJeongJKoSSHanWPoor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer SocietyJ Clin Oncol200725172360236810.1200/jco.2006.10.37541751557017515570 LeeSHLeeBShimJHLeeKWYunJWKimSYKimTYKimYHKoYHChungHCYuCSLeeJRhaSYKimTWJungKHImSAMoonHGChoSKangJHKimJKimSKRyuHSHaSYKimJIChungYJKimCKimHLParkWYNohDYParkKLandscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patientsCancer Res Treatment20195112112221:CAS:528:DC%2BC1MXhs1Ols73K10.4143/crt.2018.132 SwisherEMLinKKOzaAMScottCLGiordanoHSunJKonecnyGEColemanRLTinkerAVO'MalleyDMKristeleitRSMaLBell-McGuinnKMBrentonJDCragunJMOakninARay-CoquardIHarrellMIMannEKaufmannSHFloquetALearyAHardingTCGobleSMaloneyLIsaacsonJAllenARRolfeLYelenskyRRaponiMMcNeishIARucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol201718175871:CAS:528:DC%2BC28XhvFKnurbJ10.1016/s1470-2045(16)30559-92790859427908594 SztupinszkiZDiossyMKrzystanekMReinigerLCsabaiIFaveroFBirkbakNJEklundACSyedASzallasiZMigrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancerNPJ Breast Cancer20184161:CAS:528:DC%2BC1cXht1OjsLzI10.1038/s41523-018-0066-62997803529978035 Van LooPNordgardSHLingjaerdeOCRussnesHGRyeIHSunWWeigmanVJMarynenPZetterbergANaumeBPerouCMBorresen-DaleALKristensenVNAllele-specific copy number analysis of tumorsProc Natl Acad Sci USA201010739169101691510.1073/pnas.10098431072083753320837533 CirielloGMillerMLAksoyBASenbabaogluYSchultzNSanderCEmerging landscape of oncogenic signatures across human cancersNat Genet20134510112711331:CAS:528:DC%2BC3sXhsFWms7zM10.1038/ng.27622407185124071851 LordCJAshworthAPARP inhibitors: synthetic lethality in the clinicScience20173556330115211581:CAS:528:DC%2BC2sXktFOmtrg%3D10.1126/science.aam73442830282328302823 PartridgeAHHughesMEWarnerETOttesenRAWongYNEdgeSBTheriaultRLBlayneyDWNilandJCWinerEPWeeksJCTamimiRMSubtype-dependent relationship between young age at diagnosis and breast cancer survivalJ Clin Oncol201634273308331410.1200/jco.2015.65.80132748015527480155 Ray-CoquardIPautierPPignataSPerolDGonzalez-MartinABergerRFujiwaraKVergoteIColomboNMaenpaaJSelleFSehouliJLorussoDGuerra AliaEMReinthallerANagaoSLefeuvre-PlesseCCanzlerUScambiaGLortholaryAMarmeFCombePde GregorioNRodriguesMBuderathPDubotCBurgesAYouBPujade-LauraineEHarterPOlaparib plus bevacizumab as first-line maintenance in ovarian cancerNew Engl J Med201938125241624281:CAS:528:DC%2BC1MXisV2mt7fP10.1056/NEJMoa19113613185179931851799 JonssonPBandlamudiCChengMLSrinivasanPChavanSSFriedmanNDRosenEYRichardsALBouvierNSelcukluSDBielskiCMAbidaWMandelkerDBirsoyOZhangLZehirADonoghueMTABaselgaJOffitKScherHIO'ReillyEMStadlerZKSchultzNSocciNDVialeALadanyiMRobsonMEHymanDMBergerMFSolitDBTaylorBSTumour lineage shapes BRCA-mediated phenotypesNature201957177665765791:CAS:528:DC%2BC1MXhsVeqs7rN10.1038/s41586-019-1382-13129255031292550 MirzaMRMonkBJHerrstedtJOzaAMMahnerSRedondoAFabbroMLedermannJALorussoDVergoteIBen-BaruchNEMarthCMadryRChristensenRDBerekJSDorumATinkerAVdu BoisAGonzalez-MartinAFollanaPBenignoBRosenbergPGilbertLRimelBJBuscemaJBalserJPAgarwalSMatulonisUANiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerNew Engl J Med201637522215421641:CAS:528:DC%2BC28XitFaqt77O10.1056/NEJMoa16113102771729927717299 ZehirABenayedRShahRHSyedAMiddhaSKimHRSrinivasanPGaoJChakravartyDDevlinSMHellmannMDBarronDASchramAMHameedMDoganSRossDSHechtmanJFDeLairDFYaoJMandelkerDLChengDTChandramohanRMohantyASPtashkinRNJayakumaranGPrasadMSyedMHRemaABLiuZYNafaKBorsuLSadowskaJCasanovaJBacaresRKieckaIJRazumovaASonJBStewartLBaldiTMullaneyKAAl-AhmadieHVakianiEAbeshouseAAPensonAVJonssonPCamachoNChangMTWonHHGrossBEKundraRHeinsZJChenHWPhillipsSZhangHWangJOchoaAWillsJEubankMThomasSBGardosSMRealesDNGalleJDuranyRCambriaRAbidaWCercekAFeldmanDRGounderMMHakimiAAHardingJJIyerGJanjigianYYJordanEJKellyCMLoweryMAMorrisLGTOmuroAMRajNRazaviPShoushtariANShuklaNSoumeraiTEVargheseAMYaegerRColemanJBochnerBRielyGJSaltzLBScherHISabbatiniPJRobsonMEKlimstraDSTaylorBSBaselgaJSchultzNHymanDMArcilaMESolitDBLadanyiMBergerMFMutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNat Med20172367037131:CAS:528:DC%2BC2sXntFKitLo%3D10.1038/nm.43332848135928481359 DaviesHGlodzikDMorganellaSYatesLRStaafJZouXRamakrishnaMMartinSBoyaultSSieuwertsAMSimpsonPTKingTARaineKEyfjordJEKongGBorgABirneyEStunnenbergHGvan de VijverMJBorresen-DaleALMartensJWSpanPNLakhaniSRVincent-SalomonASotiriouCTuttAThompsonAMVan LaereSRichardsonALViariACampbellPJStrattonMRNik-ZainalSHRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesNat Med20172345175251:CAS:528:DC%2BC2sXkvFahtr4%3D10.1038/nm.42922828811028288110 SunamiKIchikawaHKuboTKatoMFujiwaraYShimomuraAKoyamaTKakishimaHKitamiMMatsushitaHFurukawaENarushimaDNagaiMTaniguchiHMotoiNSekineSMaeshimaAMoriTWatanabeRYoshidaMYoshidaAYoshidaHSatomiKSukedaAHashimotoTShimizuTIwasaSYonemoriKKatoKMorizaneCOgawaCTanabeNSuganoKHiraokaNTamuraKYoshidaTFujiwaraYOchiaiAYamamotoNKohnoTFeasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based studyCancer Sci20191104148014901:CAS:528:DC%2BC1MXmsFCjtb0%3D10.1111/cas.139693074273130742731 KohnoTImplementation of "clinical sequencing" in cancer genome medicine in JapanCancer Sci201810935075121:CAS:528:DC%2BC1cXitV2mtLs%3D10.1111/cas.134862928584829285848 ElstonCWEllisIOPatholog AH Partridge (5716_CR4) 2016; 34 SJ Isakoff (5716_CR27) 2015; 33 A Zehir (5716_CR33) 2017; 23 ML Telli (5716_CR30) 2018; 36 KA Gelmon (5716_CR9) 2011; 12 S Roychowdhury (5716_CR32) 2011; 3 P Jonsson (5716_CR19) 2019; 571 Z Sztupinszki (5716_CR24) 2018; 4 KL Huang (5716_CR42) 2018; 173 F Andre (5716_CR51) 2019; 380 A Tutt (5716_CR28) 2018; 24 TA Knijnenburg (5716_CR38) 2018; 23 5716_CR37 J Liu (5716_CR43) 2018; 173 CW Elston (5716_CR40) 1991; 19 W Zhong (5716_CR5) 2019 L Bouaoun (5716_CR47) 2016; 37 SH Ahn (5716_CR3) 2007; 25 S Jones (5716_CR31) 2015; 7 AM Marquard (5716_CR55) 2015; 3 CGA Network (5716_CR21) 2012; 490 ML Telli (5716_CR26) 2015; 33 Y Kanke (5716_CR39) 2018; 9 M Robson (5716_CR10) 2017; 377 J Murai (5716_CR18) 2012; 72 Z Kan (5716_CR22) 2018; 9 A Poti (5716_CR54) 2019; 20 PC Fong (5716_CR8) 2009; 361 N Tung (5716_CR45) 2016; 34 O Caramelo (5716_CR53) 2019; 17 RL Coleman (5716_CR16) 2019; 381 K Sunami (5716_CR34) 2019; 110 G Ciriello (5716_CR56) 2013; 45 KP Pennington (5716_CR46) 2014; 20 C Liedtke (5716_CR7) 2008; 26 A Gonzalez-Martin (5716_CR15) 2019; 381 P Van Loo (5716_CR44) 2010; 107 EM Swisher (5716_CR12) 2017; 18 JK Litton (5716_CR11) 2018; 379 H Davies (5716_CR41) 2017; 23 R Rosenthal (5716_CR48) 2016; 17 MR Mirza (5716_CR13) 2016; 375 CJ Lord (5716_CR20) 2017; 355 P Polak (5716_CR49) 2017; 49 RL Coleman (5716_CR14) 2017; 390 I Ray-Coquard (5716_CR17) 2019; 381 S Nik-Zainal (5716_CR23) 2016; 534 S Sengupta (5716_CR57) 2005; 6 SH Lee (5716_CR36) 2019; 51 5716_CR29 A Kataoka (5716_CR6) 2014; 21 S Imanishi (5716_CR50) 2019; 174 T Kohno (5716_CR35) 2018; 109 5716_CR2 ML Telli (5716_CR25) 2016; 22 BR Davies (5716_CR52) 2015; 14 5716_CR1 |
| References_xml | – reference: MarquardAMEklundACJoshiTKrzystanekMFaveroFWangZCRichardsonALSilverDPSzallasiZBirkbakNJPan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugsBiomarker Res20153910.1186/s40364-015-0033-4 – reference: GelmonKATischkowitzMMackayHSwenertonKRobidouxATonkinKHirteHHuntsmanDClemonsMGilksBYerushalmiRMacphersonECarmichaelJOzaAOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol20111298528611:CAS:528:DC%2BC3MXhtFSqs7%2FE10.1016/s1470-2045(11)70214-52186240721862407 – reference: TungNLinNUKiddJAllenBASinghNWenstrupRJHartmanARWinerEPGarberJEFrequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancerJ Clin Oncol20163413146014681:CAS:528:DC%2BC2sXisFWjsb4%3D10.1200/jco.2015.65.07472697641926976419 – reference: PolakPKimJBraunsteinLZKarlicRHaradhavalaNJTiaoGRosebrockDLivitzDKublerKMouwKWKamburovAMaruvkaYELeshchinerILanderESGolubTRZickAOrthweinALawrenceMSBatraRNCaldasCHaberDALairdPWShenHEllisenLWD'AndreaADChanockSJFoulkesWDGetzGA mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancerNat Genet20174910147614861:CAS:528:DC%2BC2sXhtlKjtbvL10.1038/ng.39342882572628825726 – reference: ImanishiSNaoiYShimazuKShimodaMKagaraNTaneiTMiyakeTKimSJNoguchiSClinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FECBreast Cancer Res Treat201917436276371:CAS:528:DC%2BC1MXnvVygsbY%3D10.1007/s10549-018-05120-93060763130607631 – reference: KnijnenburgTAWangLZimmermannMTChambweNGaoGFCherniackADFanHShenHWayGPGreeneCSLiuYAkbaniRFengBDonehowerLAMillerCShenYKarimiMChenHKimPJiaPShinbrotEZhangSLiuJHuHBaileyMHYauCWolfDZhaoZWeinsteinJNLiLDingLMillsGBLairdPWWheelerDAShmulevichIMonnatRJJrXiaoYWangCGenomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlasCell Rep2018231239254.e2361:CAS:528:DC%2BC1cXntVKqt74%3D10.1016/j.celrep.2018.03.0762961766429617664 – reference: KankeYShimomuraASaitoMHondaTShiraishiKShimadaYWatanabeRYoshidaHYoshidaMShimizuCTakahashiKTotsukaHOgiwaraHHiroseSKonoKTamuraKOkamotoAKinoshitaTKatoTKohnoTGene aberration profile of tumors of adolescent and young adult femalesOncotarget2018956228623710.18632/oncotarget.237652946406729464067 – reference: RosenthalRMcGranahanNHerreroJTaylorBSSwantonCDeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolutionGenome Biol201617311:CAS:528:DC%2BC28XpvVCltL0%3D10.1186/s13059-016-0893-42689917026899170 – reference: PenningtonKPWalshTHarrellMILeeMKPennilCCRendiMHThorntonANorquistBMCasadeiSNordASAgnewKJPritchardCCScrogginsSGarciaRLKingMCSwisherEMGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasClin Cancer Res20142037647751:CAS:528:DC%2BC2cXitFWjtL4%3D10.1158/1078-0432.Ccr-13-22872424011224240112 – reference: SunamiKIchikawaHKuboTKatoMFujiwaraYShimomuraAKoyamaTKakishimaHKitamiMMatsushitaHFurukawaENarushimaDNagaiMTaniguchiHMotoiNSekineSMaeshimaAMoriTWatanabeRYoshidaMYoshidaAYoshidaHSatomiKSukedaAHashimotoTShimizuTIwasaSYonemoriKKatoKMorizaneCOgawaCTanabeNSuganoKHiraokaNTamuraKYoshidaTFujiwaraYOchiaiAYamamotoNKohnoTFeasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based studyCancer Sci20191104148014901:CAS:528:DC%2BC1MXmsFCjtb0%3D10.1111/cas.139693074273130742731 – reference: KohnoTImplementation of "clinical sequencing" in cancer genome medicine in JapanCancer Sci201810935075121:CAS:528:DC%2BC1cXitV2mtLs%3D10.1111/cas.134862928584829285848 – reference: ZhongWTanLJiangWGChenKYouNSandersAJLiangGLiuZLingYGongCEffect of younger age on survival outcomes in T1N0M0 breast cancer: a propensity score matching analysisJ Surg Oncol201910.1002/jso.254573156283031562830 – reference: RobsonMImSASenkusEXuBDomchekSMMasudaNDelalogeSLiWTungNArmstrongAWuWGoesslCRunswickSContePOlaparib for metastatic breast cancer in patients with a germline BRCA mutationNew Engl J Med201737765235331:CAS:528:DC%2BC2sXhtlyksrbN10.1056/NEJMoa17064502857860128578601 – reference: ColemanRLOzaAMLorussoDAghajanianCOakninADeanAColomboNWeberpalsJIClampAScambiaGLearyAHollowayRWGancedoMAFongPCGohJCO'MalleyDMArmstrongDKGarcia-DonasJSwisherEMFloquetAKonecnyGEMcNeishIAScottCLCameronTMaloneyLIsaacsonJGobleSGraceCHardingTCRaponiMSunJLinKKGiordanoHLedermannJARucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201739010106194919611:CAS:528:DC%2BC2sXhsFSmt7bM10.1016/s0140-6736(17)32440-62891636728916367 – reference: ColemanRLFlemingGFBradyMFSwisherEMSteffensenKDFriedlanderMOkamotoAMooreKNEfrat Ben-BaruchNWernerTLClovenNGOakninADiSilvestroPAMorganMANamJHLeathCA3rdNicumSHagemannARLittellRDCellaDBaron-HaySGarcia-DonasJMizunoMBell-McGuinnKSullivanDMBachBABhattacharyaSRatajczakCKAnsellPJDinhMHAghajanianCBookmanMAVeliparib with first-line chemotherapy and as maintenance therapy in ovarian cancerNew Engl J Med201938125240324151:CAS:528:DC%2BC1MXisV2mt7fL10.1056/NEJMoa19097073156280031562800 – reference: Ferlay J, Colombet M, Bray F (2018) Cancer incidence in five continents, CI5plus: IARC CancerBase No. 9 [Internet]. International Agency for Research on Cancer, Lyon. https://ci5.iarc.fr. Accessed 19 May 2019 – reference: ElstonCWEllisIOPathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upHistopathology19911954034101:STN:280:DyaK38%2FpvVSltw%3D%3D10.1111/j.1365-2559.1991.tb00229.x – reference: AndreFCiruelosERubovszkyGCamponeMLoiblSRugoHSIwataHContePMayerIAKaufmanBYamashitaTLuYSInoueKTakahashiMPapaiZLonginASMillsDWilkeCHirawatSJuricDAlpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancerN Engl J Med201938020192919401:CAS:528:DC%2BC1MXhtVWis7nP10.1056/NEJMoa1813904 – reference: AhnSHSonBHKimSWKimSIJeongJKoSSHanWPoor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer SocietyJ Clin Oncol200725172360236810.1200/jco.2006.10.37541751557017515570 – reference: PotiAGyergyakHNemethERuszOTothSKovacshaziCChenDSzikrisztBSpisakSTakedaSSzakacsGSzallasiZRichardsonALSzutsDCorrelation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agentsGenome Biol20192012401:CAS:528:DC%2BC1MXitFOjtLvP10.1186/s13059-019-1867-03172711731727117 – reference: LiedtkeCMazouniCHessKRAndreFTordaiAMejiaJASymmansWFGonzalez-AnguloAMHennessyBGreenMCristofanilliMHortobagyiGNPusztaiLResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol20082681275128110.1200/jco.2007.14.4147 – reference: ClinicalTrials.gov (2018) NCT02401347. https://clinicaltrials.gov/ct2/show/NCT02401347. Accessed 15 Nov 2018 – reference: Van LooPNordgardSHLingjaerdeOCRussnesHGRyeIHSunWWeigmanVJMarynenPZetterbergANaumeBPerouCMBorresen-DaleALKristensenVNAllele-specific copy number analysis of tumorsProc Natl Acad Sci USA201010739169101691510.1073/pnas.10098431072083753320837533 – reference: KataokaATokunagaEMasudaNShienTKawabataKMiyashitaMClinicopathological features of young patients (%3c35 years of age) with breast cancer in a Japanese Breast Cancer Society supported studyBreast Cancer201421664365010.1007/s12282-013-0466-22358879123588791 – reference: SenguptaSHarrisCCp53: traffic cop at the crossroads of DNA repair and recombinationNat Rev Mol Cell Biol20056144551:CAS:528:DC%2BD2MXlvVWh10.1038/nrm15461568806615688066 – reference: CarameloOSilvaCCarameloFFrutuosoCAlmeida-SantosTThe effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysisHered Cancer Clin Pract2019171110.1186/s13053-019-0111-y3096285830962858 – reference: PartridgeAHHughesMEWarnerETOttesenRAWongYNEdgeSBTheriaultRLBlayneyDWNilandJCWinerEPWeeksJCTamimiRMSubtype-dependent relationship between young age at diagnosis and breast cancer survivalJ Clin Oncol201634273308331410.1200/jco.2015.65.80132748015527480155 – reference: Gonzalez-MartinAPothuriBVergoteIDePontCRGraybillWMirzaMRMcCormickCLorussoDHoskinsPFreyerGBaumannKJardonKRedondoAMooreRGVulstekeCO'CearbhaillRELundBBackesFBarretina-GinestaPHaggertyAFRubio-PerezMJShahinMSMangiliGBradleyWHBruchimISunKMalinowskaIALiYGuptaDMonkBJNiraparib in patients with newly diagnosed advanced ovarian cancerNew Engl J Med201938125239124021:CAS:528:DC%2BC1MXisV2mtL7F10.1056/NEJMoa19109623156279931562799 – reference: MuraiJHuangSYDasBBRenaudAZhangYDoroshowJHJiJTakedaSPommierYTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCan Res20127221558855991:CAS:528:DC%2BC38XhsF2jsLjE10.1158/0008-5472.Can-12-2753 – reference: Nik-ZainalSDaviesHStaafJRamakrishnaMGlodzikDZouXMartincorenaIAlexandrovLBMartinSWedgeDCVan LooPJuYSSmidMBrinkmanABMorganellaSAureMRLingjaerdeOCLangerodARingnerMAhnSMBoyaultSBrockJEBroeksAButlerADesmedtCDirixLDronovSFatimaAFoekensJAGerstungMHooijerGKJangSJJonesDRKimHYKingTAKrishnamurthySLeeHJLeeJYLiYMcLarenSMenziesAMustonenVO'MearaSPauporteIPivotXPurdieCARaineKRamakrishnanKRodriguez-GonzalezFGRomieuGSieuwertsAMSimpsonPTShepherdRStebbingsLStefanssonOATeagueJTommasiSTreilleuxIVan den EyndenGGVermeulenPVincent-SalomonAYatesLCaldasCVant VeerLTuttAKnappskogSTanBKJonkersJBorgAUenoNTSotiriouCViariAFutrealPACampbellPJSpanPNVan LaereSLakhaniSREyfjordJEThompsonAMBirneyEStunnenbergHGvan de VijverMJMartensJWBorresen-DaleALRichardsonALKongGThomasGStrattonMRLandscape of somatic mutations in 560 breast cancer whole-genome sequencesNature2016534760547541:CAS:528:DC%2BC28XntVCksrc%3D10.1038/nature176762713592627135926 – reference: LiuJLichtenbergTHoadleyKAPoissonLMLazarAJCherniackADKovatichAJBenzCCLevineDALeeAVOmbergLWolfDMShriverCDThorssonVHuHAn integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analyticsCell20181732400416.e4111:CAS:528:DC%2BC1cXntFaiu7Y%3D10.1016/j.cell.2018.02.0522962505529625055 – reference: SwisherEMLinKKOzaAMScottCLGiordanoHSunJKonecnyGEColemanRLTinkerAVO'MalleyDMKristeleitRSMaLBell-McGuinnKMBrentonJDCragunJMOakninARay-CoquardIHarrellMIMannEKaufmannSHFloquetALearyAHardingTCGobleSMaloneyLIsaacsonJAllenARRolfeLYelenskyRRaponiMMcNeishIARucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol201718175871:CAS:528:DC%2BC28XhvFKnurbJ10.1016/s1470-2045(16)30559-92790859427908594 – reference: LordCJAshworthAPARP inhibitors: synthetic lethality in the clinicScience20173556330115211581:CAS:528:DC%2BC2sXktFOmtrg%3D10.1126/science.aam73442830282328302823 – reference: BouaounLSonkinDArdinMHollsteinMByrnesGZavadilJOlivierMTP53 variations in human cancers: new lessons from the IARC TP53 database and genomics dataHum Mutat20163798658761:CAS:528:DC%2BC28Xhtlansb7E10.1002/humu.230352732891927328919 – reference: LeeSHLeeBShimJHLeeKWYunJWKimSYKimTYKimYHKoYHChungHCYuCSLeeJRhaSYKimTWJungKHImSAMoonHGChoSKangJHKimJKimSKRyuHSHaSYKimJIChungYJKimCKimHLParkWYNohDYParkKLandscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patientsCancer Res Treatment20195112112221:CAS:528:DC%2BC1MXhs1Ols73K10.4143/crt.2018.132 – reference: IsakoffSJMayerELHeLTrainaTACareyLAKragKJRugoHSLiuMCStearnsVComeSETimmsKMHartmanARBorgerDRFinkelsteinDMGarberJERyanPDWinerEPGossPEEllisenLWTBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancerJ Clin Oncol20153317190219091:CAS:528:DC%2BC2MXhsFKmt7zM10.1200/jco.2014.57.66602584793625847936 – reference: CirielloGMillerMLAksoyBASenbabaogluYSchultzNSanderCEmerging landscape of oncogenic signatures across human cancersNat Genet20134510112711331:CAS:528:DC%2BC3sXhsFWms7zM10.1038/ng.27622407185124071851 – reference: DaviesBRGuanNLogieACrafterCHansonLJacobsVJamesNDudleyPJacquesKLaddBD'CruzCMZindaMLindemannJKodairaMTamuraKJenkinsELTumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitorsMol Cancer Ther20151411244124511:CAS:528:DC%2BC2MXhslOgt7%2FO10.1158/1535-7163.Mct-15-02302635132326351323 – reference: FongPCBossDSYapTATuttAWuPMergui-RoelvinkMMortimerPSwaislandHLauAO'ConnorMJAshworthACarmichaelJKayeSBSchellensJHde BonoJSInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med200936121231341:CAS:528:DC%2BD1MXosVKrtrw%3D10.1056/NEJMoa09002121955364119553641 – reference: TelliMLJensenKCVinayakSKurianAWLipsonJAFlahertyPJTimmsKAbkevichVSchackmannEAWapnirILCarlsonRWChangPJSparanoJAHeadBGoldsteinLJHaleyBDakhilSRReidJEHartmanARManolaJFordJMPhase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105J Clin Oncol20153317189519011:CAS:528:DC%2BC2MXhsFKmt7zE10.1200/jco.2014.57.00852584792925847929 – reference: Ray-CoquardIPautierPPignataSPerolDGonzalez-MartinABergerRFujiwaraKVergoteIColomboNMaenpaaJSelleFSehouliJLorussoDGuerra AliaEMReinthallerANagaoSLefeuvre-PlesseCCanzlerUScambiaGLortholaryAMarmeFCombePde GregorioNRodriguesMBuderathPDubotCBurgesAYouBPujade-LauraineEHarterPOlaparib plus bevacizumab as first-line maintenance in ovarian cancerNew Engl J Med201938125241624281:CAS:528:DC%2BC1MXisV2mt7fP10.1056/NEJMoa19113613185179931851799 – reference: MirzaMRMonkBJHerrstedtJOzaAMMahnerSRedondoAFabbroMLedermannJALorussoDVergoteIBen-BaruchNEMarthCMadryRChristensenRDBerekJSDorumATinkerAVdu BoisAGonzalez-MartinAFollanaPBenignoBRosenbergPGilbertLRimelBJBuscemaJBalserJPAgarwalSMatulonisUANiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerNew Engl J Med201637522215421641:CAS:528:DC%2BC28XitFaqt77O10.1056/NEJMoa16113102771729927717299 – reference: LittonJKRugoHSEttlJHurvitzSAGoncalvesALeeKHFehrenbacherLYerushalmiRMinaLAMartinMRocheHImYHQuekRGWMarkovaDTudorICHannahALEiermannWBlumJLTalazoparib in patients with advanced breast cancer and a germline BRCA mutationNew Engl J Med201837987537631:CAS:528:DC%2BC1cXhs1eqsrnI10.1056/NEJMoa18029053011057930110579 – reference: JonssonPBandlamudiCChengMLSrinivasanPChavanSSFriedmanNDRosenEYRichardsALBouvierNSelcukluSDBielskiCMAbidaWMandelkerDBirsoyOZhangLZehirADonoghueMTABaselgaJOffitKScherHIO'ReillyEMStadlerZKSchultzNSocciNDVialeALadanyiMRobsonMEHymanDMBergerMFSolitDBTaylorBSTumour lineage shapes BRCA-mediated phenotypesNature201957177665765791:CAS:528:DC%2BC1MXhsVeqs7rN10.1038/s41586-019-1382-13129255031292550 – reference: HuangKLMashlRJWuYRitterDIWangJOhCPaczkowskaMReynoldsSWyczalkowskiMAOakNScottADKrassowskiMCherniackADHoulahanKEJayasingheRWangLBZhouDCLiuDCaoSKimYWKoireAMcMichaelJFHucthagowderVKimTBHahnAWangCMcLellanMDAl-MullaFJohnsonKJLichtargeOBoutrosPCRaphaelBLazarAJZhangWWendlMCGovindanRJainSWheelerDKulkarniSDipersioJFReimandJMeric-BernstamFChenKShmulevichIPlonSEChenFDingLPathogenic germline variants in 10,389 adult cancersCell20181732355370.e3141:CAS:528:DC%2BC1cXntFahsrg%3D10.1016/j.cell.2018.03.0392962505229625052 – reference: TuttAToveyHCheangMCUKernaghanSKilburnLGazinskaPOwenJAbrahamJBarrettSBarrett-LeePBrownRChanSDowsettMFlanaganJMFoxLGrigoriadisAGutinAHarper-WynneCHattonMQHoadleyKAParikhJParkerPPerouCMRoylanceRShahVShawASmithIETimmsKMWardleyAMWilsonGGillettCLanchburyJSAshworthARahmanNHarriesMEllisPPinderSEBlissJMCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialNat Med20182456286371:CAS:528:DC%2BC1cXovVWrsrs%3D10.1038/s41591-018-0009-72971308629713086 – reference: DaviesHGlodzikDMorganellaSYatesLRStaafJZouXRamakrishnaMMartinSBoyaultSSieuwertsAMSimpsonPTKingTARaineKEyfjordJEKongGBorgABirneyEStunnenbergHGvan de VijverMJBorresen-DaleALMartensJWSpanPNLakhaniSRVincent-SalomonASotiriouCTuttAThompsonAMVan LaereSRichardsonALViariACampbellPJStrattonMRNik-ZainalSHRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesNat Med20172345175251:CAS:528:DC%2BC2sXkvFahtr4%3D10.1038/nm.42922828811028288110 – reference: Cancer Information Service, National Cancer Center, Japan (2019) Cancer registry and statistics. https://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed 17 May 2019. – reference: NetworkCGAComprehensive molecular portraits of human breast tumoursNature2012490741861701:CAS:528:DC%2BC38XhtlyltrvN10.1038/nature11412 – reference: JonesSAnagnostouVLytleKParpart-LiSNesselbushMRileyDRShuklaMChesnickBKadanMPappEGalensKGMurphyDZhangTKannLSausenMAngiuoliSVDiazLAJrVelculescuVEPersonalized genomic analyses for cancer mutation discovery and interpretationSci Transl Med201572832532831:CAS:528:DC%2BC2MXnvFKnt7Y%3D10.1126/scitranslmed.aaa7161 – reference: RoychowdhurySIyerMKRobinsonDRLonigroRJWuYMCaoXKalyana-SundaramSSamLBalbinOAQuistMJBarretteTEverettJSiddiquiJKunjuLPNavoneNAraujoJCTroncosoPLogothetisCJInnisJWSmithDCLaoCDKimSYRobertsJSGruberSBPientaKJTalpazMChinnaiyanAMPersonalized oncology through integrative high-throughput sequencing: a pilot studySci Transl Med201131111111211:CAS:528:DC%2BC3MXhs1KhsL3L10.1126/scitranslmed.3003161 – reference: TelliMLMetzgerOTimmsKEvansBVogelDWeiHJonesJTWenstrupRJMcKeeMDSullivanDMFallstromMMaagDAnsellPJSohnJChenS-TMartinezNGeyerCELoiblSGolshanMEvaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBCJ Clin Oncol20183615_suppl51951910.1200/JCO.2018.36.15_suppl.519 – reference: ZehirABenayedRShahRHSyedAMiddhaSKimHRSrinivasanPGaoJChakravartyDDevlinSMHellmannMDBarronDASchramAMHameedMDoganSRossDSHechtmanJFDeLairDFYaoJMandelkerDLChengDTChandramohanRMohantyASPtashkinRNJayakumaranGPrasadMSyedMHRemaABLiuZYNafaKBorsuLSadowskaJCasanovaJBacaresRKieckaIJRazumovaASonJBStewartLBaldiTMullaneyKAAl-AhmadieHVakianiEAbeshouseAAPensonAVJonssonPCamachoNChangMTWonHHGrossBEKundraRHeinsZJChenHWPhillipsSZhangHWangJOchoaAWillsJEubankMThomasSBGardosSMRealesDNGalleJDuranyRCambriaRAbidaWCercekAFeldmanDRGounderMMHakimiAAHardingJJIyerGJanjigianYYJordanEJKellyCMLoweryMAMorrisLGTOmuroAMRajNRazaviPShoushtariANShuklaNSoumeraiTEVargheseAMYaegerRColemanJBochnerBRielyGJSaltzLBScherHISabbatiniPJRobsonMEKlimstraDSTaylorBSBaselgaJSchultzNHymanDMArcilaMESolitDBLadanyiMBergerMFMutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNat Med20172367037131:CAS:528:DC%2BC2sXntFKitLo%3D10.1038/nm.43332848135928481359 – reference: U.S. Food and Drug Administration (2017) FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.html. Accessed 10 May 2019 – reference: TelliMLTimmsKMReidJHennessyBMillsGBJensenKCSzallasiZBarryWTWinerEPTungNMIsakoffSJRyanPDGreene-ColozziAGutinASangaleZIlievDNeffCAbkevichVJonesJTLanchburyJSHartmanARGarberJEFordJMSilverDPRichardsonALHomologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancerClin Cancer Res20162215376437731:CAS:528:DC%2BC28Xht1yhtbrM10.1158/1078-0432.Ccr-15-24772695755426957554 – reference: SztupinszkiZDiossyMKrzystanekMReinigerLCsabaiIFaveroFBirkbakNJEklundACSyedASzallasiZMigrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancerNPJ Breast Cancer20184161:CAS:528:DC%2BC1cXht1OjsLzI10.1038/s41523-018-0066-62997803529978035 – reference: KanZDingYKimJJungHHChungWLalSChoSFernandez-BanetJLeeSKKimSWLeeJEChoiYLDengSKimJYAhnJSShaYMuXJNamJYImYHLeeSParkWYNamSJParkYHMulti-omics profiling of younger Asian breast cancers reveals distinctive molecular signaturesNat Commun20189117251:CAS:528:DC%2BC1cXhtFeltL%2FL10.1038/s41467-018-04129-42971300329713003 – volume: 379 start-page: 753 issue: 8 year: 2018 ident: 5716_CR11 publication-title: New Engl J Med doi: 10.1056/NEJMoa1802905 – volume: 51 start-page: 211 issue: 1 year: 2019 ident: 5716_CR36 publication-title: Cancer Res Treatment doi: 10.4143/crt.2018.132 – volume: 381 start-page: 2391 issue: 25 year: 2019 ident: 5716_CR15 publication-title: New Engl J Med doi: 10.1056/NEJMoa1910962 – volume: 571 start-page: 576 issue: 7766 year: 2019 ident: 5716_CR19 publication-title: Nature doi: 10.1038/s41586-019-1382-1 – volume: 109 start-page: 507 issue: 3 year: 2018 ident: 5716_CR35 publication-title: Cancer Sci doi: 10.1111/cas.13486 – volume: 377 start-page: 523 issue: 6 year: 2017 ident: 5716_CR10 publication-title: New Engl J Med doi: 10.1056/NEJMoa1706450 – volume: 381 start-page: 2403 issue: 25 year: 2019 ident: 5716_CR16 publication-title: New Engl J Med doi: 10.1056/NEJMoa1909707 – volume: 380 start-page: 1929 issue: 20 year: 2019 ident: 5716_CR51 publication-title: N Engl J Med doi: 10.1056/NEJMoa1813904 – volume: 19 start-page: 403 issue: 5 year: 1991 ident: 5716_CR40 publication-title: Histopathology doi: 10.1111/j.1365-2559.1991.tb00229.x – volume: 173 start-page: 400 issue: 2 year: 2018 ident: 5716_CR43 publication-title: Cell doi: 10.1016/j.cell.2018.02.052 – volume: 33 start-page: 1895 issue: 17 year: 2015 ident: 5716_CR26 publication-title: J Clin Oncol doi: 10.1200/jco.2014.57.0085 – volume: 381 start-page: 2416 issue: 25 year: 2019 ident: 5716_CR17 publication-title: New Engl J Med doi: 10.1056/NEJMoa1911361 – ident: 5716_CR37 – year: 2019 ident: 5716_CR5 publication-title: J Surg Oncol doi: 10.1002/jso.25457 – volume: 173 start-page: 355 issue: 2 year: 2018 ident: 5716_CR42 publication-title: Cell doi: 10.1016/j.cell.2018.03.039 – volume: 7 start-page: 253 issue: 283 year: 2015 ident: 5716_CR31 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaa7161 – ident: 5716_CR1 – volume: 107 start-page: 16910 issue: 39 year: 2010 ident: 5716_CR44 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1009843107 – volume: 14 start-page: 2441 issue: 11 year: 2015 ident: 5716_CR52 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.Mct-15-0230 – volume: 22 start-page: 3764 issue: 15 year: 2016 ident: 5716_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.Ccr-15-2477 – volume: 20 start-page: 240 issue: 1 year: 2019 ident: 5716_CR54 publication-title: Genome Biol doi: 10.1186/s13059-019-1867-0 – volume: 3 start-page: 9 year: 2015 ident: 5716_CR55 publication-title: Biomarker Res doi: 10.1186/s40364-015-0033-4 – volume: 21 start-page: 643 issue: 6 year: 2014 ident: 5716_CR6 publication-title: Breast Cancer doi: 10.1007/s12282-013-0466-2 – volume: 17 start-page: 31 year: 2016 ident: 5716_CR48 publication-title: Genome Biol doi: 10.1186/s13059-016-0893-4 – volume: 355 start-page: 1152 issue: 6330 year: 2017 ident: 5716_CR20 publication-title: Science doi: 10.1126/science.aam7344 – volume: 17 start-page: 11 year: 2019 ident: 5716_CR53 publication-title: Hered Cancer Clin Pract doi: 10.1186/s13053-019-0111-y – volume: 20 start-page: 764 issue: 3 year: 2014 ident: 5716_CR46 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.Ccr-13-2287 – volume: 390 start-page: 1949 issue: 10106 year: 2017 ident: 5716_CR14 publication-title: Lancet doi: 10.1016/s0140-6736(17)32440-6 – volume: 23 start-page: 703 issue: 6 year: 2017 ident: 5716_CR33 publication-title: Nat Med doi: 10.1038/nm.4333 – volume: 110 start-page: 1480 issue: 4 year: 2019 ident: 5716_CR34 publication-title: Cancer Sci doi: 10.1111/cas.13969 – volume: 6 start-page: 44 issue: 1 year: 2005 ident: 5716_CR57 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm1546 – ident: 5716_CR2 – ident: 5716_CR29 – volume: 26 start-page: 1275 issue: 8 year: 2008 ident: 5716_CR7 publication-title: J Clin Oncol doi: 10.1200/jco.2007.14.4147 – volume: 72 start-page: 5588 issue: 21 year: 2012 ident: 5716_CR18 publication-title: Can Res doi: 10.1158/0008-5472.Can-12-2753 – volume: 4 start-page: 16 year: 2018 ident: 5716_CR24 publication-title: NPJ Breast Cancer doi: 10.1038/s41523-018-0066-6 – volume: 3 start-page: 111 issue: 111 year: 2011 ident: 5716_CR32 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3003161 – volume: 375 start-page: 2154 issue: 22 year: 2016 ident: 5716_CR13 publication-title: New Engl J Med doi: 10.1056/NEJMoa1611310 – volume: 36 start-page: 519 issue: 15_suppl year: 2018 ident: 5716_CR30 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.519 – volume: 45 start-page: 1127 issue: 10 year: 2013 ident: 5716_CR56 publication-title: Nat Genet doi: 10.1038/ng.2762 – volume: 9 start-page: 1725 issue: 1 year: 2018 ident: 5716_CR22 publication-title: Nat Commun doi: 10.1038/s41467-018-04129-4 – volume: 24 start-page: 628 issue: 5 year: 2018 ident: 5716_CR28 publication-title: Nat Med doi: 10.1038/s41591-018-0009-7 – volume: 12 start-page: 852 issue: 9 year: 2011 ident: 5716_CR9 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(11)70214-5 – volume: 174 start-page: 627 issue: 3 year: 2019 ident: 5716_CR50 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-018-05120-9 – volume: 37 start-page: 865 issue: 9 year: 2016 ident: 5716_CR47 publication-title: Hum Mutat doi: 10.1002/humu.23035 – volume: 25 start-page: 2360 issue: 17 year: 2007 ident: 5716_CR3 publication-title: J Clin Oncol doi: 10.1200/jco.2006.10.3754 – volume: 23 start-page: 517 issue: 4 year: 2017 ident: 5716_CR41 publication-title: Nat Med doi: 10.1038/nm.4292 – volume: 490 start-page: 61 issue: 7418 year: 2012 ident: 5716_CR21 publication-title: Nature doi: 10.1038/nature11412 – volume: 33 start-page: 1902 issue: 17 year: 2015 ident: 5716_CR27 publication-title: J Clin Oncol doi: 10.1200/jco.2014.57.6660 – volume: 9 start-page: 6228 issue: 5 year: 2018 ident: 5716_CR39 publication-title: Oncotarget doi: 10.18632/oncotarget.23765 – volume: 34 start-page: 1460 issue: 13 year: 2016 ident: 5716_CR45 publication-title: J Clin Oncol doi: 10.1200/jco.2015.65.0747 – volume: 23 start-page: 239 issue: 1 year: 2018 ident: 5716_CR38 publication-title: Cell Rep doi: 10.1016/j.celrep.2018.03.076 – volume: 49 start-page: 1476 issue: 10 year: 2017 ident: 5716_CR49 publication-title: Nat Genet doi: 10.1038/ng.3934 – volume: 34 start-page: 3308 issue: 27 year: 2016 ident: 5716_CR4 publication-title: J Clin Oncol doi: 10.1200/jco.2015.65.8013 – volume: 361 start-page: 123 issue: 2 year: 2009 ident: 5716_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa0900212 – volume: 534 start-page: 47 issue: 7605 year: 2016 ident: 5716_CR23 publication-title: Nature doi: 10.1038/nature17676 – volume: 18 start-page: 75 issue: 1 year: 2017 ident: 5716_CR12 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(16)30559-9 |
| SSID | ssj0009709 |
| Score | 2.3379219 |
| Snippet | Purpose
Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent... Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of... Purpose Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent... PurposeHomologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 491 |
| SubjectTerms | Adolescent Adolescents Adult Analysis Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Biotechnology BRCA1 protein BRCA1 Protein - genetics BRCA2 Protein - genetics Breast - pathology Breast - surgery Breast cancer Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer research Carboplatin Cohort Studies Drug Resistance, Neoplasm - genetics Epidemiology Europe Female Genetic analysis Genetic Testing - statistics & numerical data Genotype & phenotype Germ-Line Mutation Homologous recombination Homologous Recombination - genetics Humans Japan Loss of Heterozygosity Mastectomy Medical colleges Medicine Medicine & Public Health Models, Genetic Mutation Oncology p53 Protein Phenotypes Platinum Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Prediction models Predictive Value of Tests Risk Factors Teenagers Tumor proteins Tumor Suppressor Protein p53 - genetics United States Whole Exome Sequencing Young Adult Young adults Youth |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3faxQxEA61heKLaK26Wm0Kgg8a7P5M7kmKWIpQX2rh3kIym8WC3bvenQ_97ztfNnfXK9jX3dkf2ZlJvtmZfCPER-94lc1DoUaetKq8GSnvylIx9DAuFHkVYuuE81_N2WX1c1yP0w-3eSqrXM6JcaJuJ4R_5F-R_zEAIPrb9EahaxSyq6mFxhOxA-oylHTpsV6T7uqhxAPc3o05btKmmbR1jiMjheCJEUvOUfXGwvRwer63Pj1ImMZ16PS5eJYApDwZNP5CbIV-T-yepxT5S3FzcQXCXzmd4RA-u4zdbiSjU_lnco3JjqN9iUj4msPiqBnZBjBJYBumvOqlR6X6QhIsYjbHkXvET9L1rbzFJCEjecd8X1ye_vj9_UylvgqK6nK0ULVreMFCbOSpCS5Q4RiFBaobMihba_POdWClYXiVF6H0TteOfbcrvdFet-Ursd1P-vBGSEdtRwbJP0MVUed0YEzVdVQBWIUiE_nyo1pKpOPoffHXrumSoQjLirBREfY4E59X10wHyo1HpQ-hKztsG135qz3hSM1oJHkz8SlKwGP52eTSxgMeAbivNiQPNiTZ02jz9NIebPL0uV3bZSaOVqdxJarX-sAaZRlGZSOGgizzerCj1cgY0BoGqWUmviwNa33z_w_77ePv8k48LaJto674QGwvZv_Ce0ZPC_8husgdulMTTw priority: 102 providerName: ProQuest |
| Title | Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults |
| URI | https://link.springer.com/article/10.1007/s10549-020-05716-0 https://www.ncbi.nlm.nih.gov/pubmed/32488393 https://www.proquest.com/docview/2413800457 https://www.proquest.com/docview/2409193997 |
| Volume | 182 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS-RAEC58gHgRdV2Nj7EXFjy4AfPsnuOMzCiKg7gOjKemu9NBQaPOjAf_vVWdZB7iLnhJIKkkdKqq-yuq6muA31rhKhvY0G9qw_1Yi6avVRT5CD2EsmEQW7d1wlUvPe_HF4NkUDWFjepq9zol6WbqmWY3jGV8CncQYwQYBy_CckKxO1pxP2xNqXZ5WdhBjN6pOEmrVpmv3zG3HH2elGdWpU9pUrf6dNdhrYKNrFXqeQMWbLEJK1dVYvwHvP59IJpf9jKkS_SzmdvjhiEmZffPTzTFYYzPKP59wmDY6YNllvgjqPmSPRRMU336mBmyg-GIrszQPTFVZOydpgbmKDtGW9Dvdm5Pz_1qNwXfJFFz7CcqxWWKIiJtUqusCRViL2uS1AgqVsuCXOXERYOgKghtpBVPFHpsHmnBNc-in7BUPBd2B5gyWW4EpfyEiY3JFbeIpPLcxASnbOhBUP9UaSqqcdrx4lFOSZJJERIVIZ0i5IkHx5NnXkqijf9KH5KuZNksOvFS2cL4THBK7Xpw5CTIT_HbRlXtBjgCYryak9yfk0T_MvO3a3uQlX-PJGUjBcFh7sGvyW16kmrWCosaRRnEYk0EgCizXdrRZGQIYwVC08iDP7VhTV_-72Hvfk98D1ZDZ-tUXbwPS-Phmz1ADDXWDVjkA45HcRo0YLnVbbd7dD67u-zgud3pXd80nFt9AMN4Fpo |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9tAEB7RILVcqpa-TGnZSq04tKvi9-aAEG1BoZAItSBx2-6u1wIJnBAHVfyp_sbOrNcJQYIbV3vsxJ7Z2W88M98AfNQKd9nQRryrTc4TLbpcqzjmCD2EslGYWDc6oT_IesfJz5P0ZAH-tb0wVFbZ-kTnqIuhoW_kXyn_IwiA5FujS05Toyi72o7QaMxi317_xZCt3tz7gfr9FEW7O0ffe9xPFeAmjbsTnqoM3TVFBtpkVlkTKcQg1qSZEVS0VYSlKomTBcFFGNlYqzxVaLllrEWu8yLG-z6CxSTGUKYDi992Boe_ZjS_eVNUQmzimdjIfJuOb9bDWIxTuIYYKcQ4fm4rvL0h3NgRb6Vo3c63-wyeesjKthsbew4LtlqGx32flH8Bl7_PiGKYjcZ0iBTN3HwdhniYnQ4vyL0Or2pGsfcFBuLOFlhhibuCGj_ZWcU01cZPmCEbHNd05AbVFFNVwa7JLTFHF1K_hOMHeeevoFMNK_sGmDJFaQSlG4VJjClVbhHFlaVJCMrZKICwfanSeJpzmrZxLmcEzaQIiYqQThFyI4DP02tGDcnHvdJrpCvZNKpOPYTcxthQ5JRWDmDdSZCPwN82yrc64BMQ29ac5OqcJK5tM3-6tQfpfUstZyshgA_T03Ql1ctVFjWKMogDuwg-UeZ1Y0fTJ0MILRAWxwF8aQ1rdvO7H3vl_v-yBk96R_0DebA32H8LS5Gzc6pqXoXOZHxl3yF2m-j3fsEw-PPQa_Q_h1VQ3A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RkFAvFaWvAC2u1KqH1oI87T1UFSqsoBRUqUXam2s7jopUsstmEeKv8euYcZxdFgluXJPJw5mHv8m8AD4Yjbts7BLeM1bwzMgeNzpNOUIPqV0SZ86PTjg6LvZPsh-DfLAA110tDKVVdjbRG-pyaOkf-RbFfyQBELFVhbSIX7v9b6NzThOkKNLajdNoReTQXV2i-9Z8PdhFXn9Mkv7en-_7PEwY4DZPexOe6wJNN3kJxhZOO5toxCPO5oWVlMBVxpWuqD8LAo04canRItcoxVVqpDCiTPG-T2BJpHlMOiYGYtbwV7TpJdRXvJDbRSjYCWV76JVxctwQLcXo0c9tine3hlt7451grd8D-yvwLIBXttNK23NYcPUqLB-F8PwLOP99Ss2G2WhMh4jlzE_aYYiM2b_hGRna4UXDyAs_Q5fcSwUrHXWxoBJQdlozQ1nyE2ZJGscNHbnVdIrpumRXZKCYbxzSvISTR_nir2CxHtbuDTBty8pKCjxKm1lbaeEQz1WVzQjUuSSCuPuoyoaG5zR347-atWomRihkhPKMUNsRfJ5eM2rbfTxIvUm8Um3J6tRWqB30EqWgAHMEnzwFWQt8ttWh6AFXQH235ig35ihRy-386U4eVLAyjZrpRATvp6fpSsqcqx1yFGkQEfYQhiLN61aOpitDMC0RIKcRfOkEa3bz-5e99vC7bMIyaqb6eXB8uA5PEy_mlN68AYuT8YV7iyBuYt55bWHw97HV8wa4r1Os |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simple+prediction+model+for+homologous+recombination+deficiency+in+breast+cancers+in+adolescents+and+young+adults&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=Watanabe%2C+Tomoko&rft.au=Honda%2C+Takayuki&rft.au=Totsuka%2C+Hirohiko&rft.au=Yoshida%2C+Masayuki&rft.date=2020-07-01&rft.pub=Springer+US&rft.issn=0167-6806&rft.eissn=1573-7217&rft.volume=182&rft.issue=2&rft.spage=491&rft.epage=502&rft_id=info:doi/10.1007%2Fs10549-020-05716-0&rft.externalDocID=10_1007_s10549_020_05716_0 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon |